Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Truist Financial Remains a Buy on Praxis Precision Medicines (PRAX)
TD Cowen Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Praxis Precision Medicines (PRAX) Receives a Buy From TD Cowen
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target
Praxis Precision Medicine Analyst Ratings
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $120
Optimistic Outlook for Praxis Precision Medicines: Buy Rating Justified by Strategic Advancements and Positive Trial Results
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $150
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $143
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $151
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $120 to $170
Wedbush Adjusts Price Target on Praxis Precision Medicines to $51 From $48, Maintains Neutral Rating
Praxis Precision Med Is Maintained at Buy by Needham
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $145
Buy Rating Affirmed for Praxis Precision Medicines Amid Positive Epilepsy Drug Data
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT) and Praxis Precision Medicines (PRAX)
Buy Rating Justified by Promising Drug Pipeline and Financial Health at Praxis Precision Medicines